Loading news...
GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Dividend--Northpointe Bancshares, Inc. Declares Quarterly Cash Dividend on Common Stock.
GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Earnings--Northpointe Bancshares, Inc. Announces Date of Fourth Quarter 2025 Earnings Release.
GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #NPB--Northpointe Bancshares, Inc. Announces Completion of $70 Million Subordinated Notes Offering.
NPB, WTBA and CZWI within the Zacks Savings & Loan Industry will gain relatively lower interest rates. Also, digital upgrades will improve operating efficiency.
Timberland Bancorp (NASDAQ: TSBK - Get Free Report) and Northpointe Bancshares (NYSE: NPB - Get Free Report) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability. Earnings and Valuation This table compares Timberland
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX) Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more effective and durable treatment than the current standard of care for patients with wet AMD and DME Company core asset, givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, continues to advance under previously announced investment plans ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NovaBridge or the Company) today announced that it has changed its corporate name from I-Mab to NovaBridge Biosciences.
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Northpointe Bancshares is upgraded to Buy, reflecting strong earnings growth and an attractive valuation after initial caution post-IPO. NPB's Mortgage Purchase Program drove a 65% annualized increase in value, while its deposit base has grown 35% in the last 12 months. Despite heavy mortgage exposure and sector risks, NPB's forward P/E of 7.7 and price below book value present compelling value versus peers.
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, today announced that updated data from the Phase 1 study (NCT04900818) of givastomig as a monotherapy in heavily pre-treated patients (n=45) with gastroesophageal carcinoma (GEC) will be presented as a “short-talk” at the Triple Meeting on October 23, 2025 in Boston, Massachusetts (Presentation #B016). Givastomig is a bispecific antibody targeting CLDN18.2 (Claudin 18.2) and 4-1BB.
Northpointe Bancshares, Inc. (NYSE:NPB ) Q3 2025 Earnings Call October 22, 2025 10:00 AM EDT Company Participants Bradley Howes - Executive VP & CFO Charles Williams - Founder, Chairman & CEO Kevin Comps - President & Secretary Conference Call Participants Crispin Love - Piper Sandler & Co., Research Division Damon Del Monte - Keefe, Bruyette, & Woods, Inc., Research Division Presentation Operator Greetings. Welcome to Northpointe Bancshares, Inc. Third Quarter 2025 Earnings Call.
GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Earnings--Northpointe Bancshares, Inc. Reports Third Quarter 2025 Results.
I-Mab (NASDAQ:IMAB ) Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDT Company Participants Xi-Yong Fu - CEO & Director Wei Fu - Executive Chairman Emmett T. Cunningham Kyler Lei Conference Call Participants PJ Kelleher Daina Graybosch - Leerink Partners LLC, Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division Presentation Operator Good day, and welcome to the I-Mab Business Update Call.
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, announced its new business model, focused on its global capabilities built to accelerate access to innovative medicines and to enable broad strategic growth. The Company announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences.
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md. , Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U. S. -based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated patients with gastroesophageal carcinoma (GEC) has been accepted as a "short-talk" at the AACR-NCI-EORTC conference which will be held October 22-26 in Boston, Massachusetts.
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Dividend--Northpointe Bancshares, Inc. announced today that its Board of Directors has declared a quarterly cash dividend.
IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- #Earnings--Northpointe Bancshares, Inc. announces third quarter 2025 financial results will be released on Tuesday, October 21, 2025, after market close.
I-Mab has pivoted to focus on givastomig for gastric cancer, after divesting its original China portfolio and revamping leadership. Givastomig shows superior early efficacy versus rivals, with promising ORR and safety, but key Phase 1b/2 data in Q1 2026 will be critical. Despite past setbacks, I-Mab's cash runway and undervalued market cap position it for potential upside if upcoming data is positive.